Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOD001 in AL amyloidosis
NCT01707264Phase 2Completed
- Sponsor
- Prothena Corporation
- Start
- Apr 2013
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
A Phase 2 trial of birtamimab in light-chain amyloidosis, sponsored by Prothena Corporation. Started Apr 2013; status: completed.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT01707264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01707264.